Dec 1, 2008 - Biovail Corporation today announced that the USFDA has accepted the Company's abbreviated new drug application for a generic formulation of 200mg, 300mg and 400mg strengths of quetiapine fumarate extended-release tablets. This represents Biovail's third successful ANDA filing in 2008.
The details can be read here.
No comments:
Post a Comment